$VERA News

Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results

Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine

Vera Therapeutics Announces Its ORIGIN 3 Study Of TRUTAKNA In Adults With Primary IgA Nephropathy Achieves Primary Endpoint Of Proteinuria Reduction At 36 Weeks

Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast

Leerink Partners Initiates Coverage On Vera Therapeutics with Market Perform Rating, Announces Price Target of $34

Do Vera Therapeutics' (VERA) High-Profile IgAN Data Show Durable Moat or Crowded Mechanism Risk?

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

Vera Therapeutics To Present Multiple Presentations At American Society Of Nephrology Kidney Week 2026 For Its Final Efficacy Analysis Of ORIGIN 3 Study Of TRUTAKNA In IgA Nephropathy

Vera Therapeutics (VERA) Says TRUTAKNA Met All Phase III Endpoints

Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Vera set up for full approval for Trutakna in IgAN with Phase III win

Vera Therapeutics: Why I'm Sticking With 'Hold' Despite Today's Positive Trutakna Data

Vera Therapeutics Shares Rise 13% After TRUTAKNA Meets ORIGIN 3 Trial Endpoints

Vera Makes A Bullish Move — Times Three. Will It Hold Up To Competition?

VERA Stock Jumps 16% Premarket – Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4

What's Going on With Vera Therapeutics Stock on Tuesday?

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy

Vera Therapeutics Announces TRUTAKNA Meets All Prespecified Endpoints Of Final Efficacy Analysis Of ORIGIN 3 Trial In Adults With Primary IgA Nephropathy At Risk For Disease Progression

JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83